Pre-exposure prophylaxis involves people who do not have HIV taking antiretroviral drugs when they are at risk of exposure to HIV in order to prevent infection. The drugs are usually taken as pills (oral PrEP). Visit our Microbicides section for information on the development of topical PrEP products.

PrEP: latest news

PrEP resources

  • How to get PrEP in the UK

    In England, PrEP is available to people taking part in the PrEP Impact trial.In Wales, Scotland and Northern Ireland, PrEP is available through NHS sexual health clinics.It...

    From: Factsheets

    Information level Level 2
  • Pre-exposure prophylaxis (PrEP)

    PrEP is highly effective in preventing the sexual transmission of HIV. For PrEP to work well, it’s important to take the pills regularly.While PrEP can...

    From: Factsheets

    Information level Level 2
  • Using anti-HIV drugs to prevent HIV

    The goal of HIV treatment is an undetectable viral load. An undetectable viral load means that your blood has a level of HIV below the level which...

    From: Booklets

    Information level Level 2
  • PrEP

    This briefing paper provides an overview of pre-exposure prophylaxis (PrEP) for people planning, commissioning or providing HIV prevention activities in the UK. It does this by reviewing...

    From: HIV prevention briefing papers

  • Pre-exposure prophylaxis

    Pre-exposure prophylaxis is an experimental HIV-prevention strategy that would use antiretrovirals (ARVs) to protect HIV-negative people from HIV infection....

    From: Preventing HIV

    Information level Level 4

PrEP features

PrEP news from aidsmap

More news

PrEP news selected from other sources

  • CytoDyn Signs Groundbreaking Memorandum of Understanding with Thai Red Cross AIDS Research Centre to Study Pre-Exposure Prophylaxis Use of Leronlimab (PRO 140) in People at High Risk of Acquiring HIV

    “The rationale for the use of leronlimab as PrEP is grounded in the long-standing observation that individuals deficient for the CCR5 co-receptor are nearly completely resistant to sexual transmission of HIV,” said Dr. Jonah Sacha, Associate Professor of the Oregon Health & Science University. Dr. Sacha continued, “Given the difficulties many patients face with adherence to daily oral antiretroviral therapy drugs as PrEP, once-weekly leronlimab as PrEP could be transformative in slowing the epidemic.”

    20 June 2019 | CytoDyn press release
  • My PrEP Story: Leander (part 3)

    I recently chatted with someone on Grindr who told me he “only did safe”. I asked him if that meant he preferred to use condoms. He said that’s obviously what ‘safe’ meant.

    17 June 2019 | Prepster
  • Ireland: PrEP programme to reduce HIV rates to be rolled out later this year

    THE PrEP HIV prevention programme will be implemented in 2019, Health Minister Simon Harris said today. “We want to reduce the number of new HIV diagnoses in Ireland. Increasing the availability of PrEP will help us to do so. This report not only confirms that PrEP can help to prevent HIV amongst those who are high risk, it also shows how a PrEP programme could save money,” said Harris.

    17 June 2019 | Journal.ie
  • Ireland: HIV programme ‘will be undermined’ by lack of capacity

    Thousands of people are being turned away from sexual health clinics across the Republic, which will undermine a programme for preventing HIV due to be introduced later this year, according to Fianna Fáil. The PrEP (pre-exposure prophylaxis) HIV prevention programme is being implemented by the Government following advice from the State’s health watchdog that it would be safe and cost-effective.

    17 June 2019 | Irish Times
  • The truth is you can afford the medication that prevents HIV. Here’s how.

    It’s not the cost of PrEP that keeps more patients from accessing it; it’s the lack of awareness and the daunting nature of our complicated healthcare system.

    24 May 2019 | LGBTQ Nation
  • A Million Americans Need This Drug. Trump’s Deal Won’t Help Enough of Them.

    A donation of H.I.V.-prevention drugs from the pharmaceutical giant Gilead could benefit shareholders more than patients.

    14 May 2019 | The New York Times (editorial)
  • Generic HIV prevention drug coming in 2020, Gilead says

    "Gilead reached an agreement with Teva Pharmaceuticals in 2014 to allow the early launch of a generic version of Truvada into the market in 2020, a year earlier than required," wrote Douglas Brooks, Gilead's executive director for community engagement, in an email shared with NBC News by the advocacy group PrEP4All.

    09 May 2019 | CNBC
  • Official Statement responding to Gilead Sciences’ announcement that it will allow Teva to Manufacture a Generic Version of Truvada

    While Gilead’s announcement that generic Truvada will be made available in the United States a year early is a victory for the LGBTQ+ community, for HIV activists, and for U.S. taxpayers, this should only be the beginning. Even their announcement today leaves Gilead with exclusive rights to Truvada as PrEP for another 15 months and Teva as the only generic manufacturer on the U.S. market. This will do little to reduce the price in a way that will increase access and PrEP4All remains suspicious of the terms and lack of transparency surrounding the Teva settlement.

    09 May 2019 | Breakthepatent.org
  • PrEP 2-1-1 offered at Magnet, San Francisco

    For the first time in the U.S., PrEP “on-demand” dosing is being offered routinely at the San Francisco AIDS Foundation sexual health clinic Magnet.

    08 May 2019 | BETA blog
  • Why PrEP Matters For Trans People Like Me

    Taking that first pill was so much more than just swallowing medication – it was a ceremonial moment for my wellbeing.

    03 May 2019 | HuffPost
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.